Human epidermal growth factor receptor 2 (HER2) is an oncogenic driver, and a well-established therapeutic target in breast and gastric cancers. Using functional and genomic analyses of patient-derived xenografts, we previously showed that a subset (approximately 5%) of metastatic colorectal cancer (CRC) tumors is driven by amplification or mutation of HER2. This paper reviews the role of HER2 amplification as an oncogenic driver, a prognostic and predictive biomarker, and a clinically actionable target in CRC, considering the specifics of HER2 testing in this tumor type. While the role of HER2 as a biomarker for prognosis in CRC remains uncertain, its relevance as a therapeutic target has been established. Indeed, independent studies documented substantial clinical benefit in patients treated with biomarker-driven HER2-targeted therapies, with an impact on response rates and duration of response that compared favorably with immunotherapy and other examples of precision oncology. HER2-targeted therapeutic strategies have the potential to change the treatment paradigm for a clinically relevant subgroup of metastatic CRC patients.
Targeting the human epidermal growth factor receptor 2 (HER2) oncogene in colorectal cancer / S. Siena, A. Sartore Bianchi, S. Marsoni, H.I. Hurwitz, S.J. Mccall, F. Penault-Llorca, S. Srock, A. Bardelli, L. Trusolino. - In: ANNALS OF ONCOLOGY. - ISSN 0923-7534. - 29:5(2018 May 01), pp. 1108-1119.
|Titolo:||Targeting the human epidermal growth factor receptor 2 (HER2) oncogene in colorectal cancer|
|Parole Chiave:||biomarker; colorectal cancer; HER2; targeted therapies|
|Settore Scientifico Disciplinare:||Settore MED/06 - Oncologia Medica|
|Data di pubblicazione:||1-mag-2018|
|Digital Object Identifier (DOI):||http://dx.doi.org/10.1093/annonc/mdy100|
|Appare nelle tipologie:||01 - Articolo su periodico|